Summary: Physicians and teaching hospitals in the United States receive approximately $7 billion from the pharmaceutical industry annually.1 These payments have been associated with higher-cost, brand-name pharmaceutical prescribing.2-4 Whether industry payments are associated with physician treatment choice in oncology is uncertain. We examined the association between oncologists’ receipt of payments from pharmaceutical manufacturers and drug selection in 2 situations where there are multiple treatment options.
Citation:
Aaron P. Mitchell, MD, Aaron N. Winn, PhD, MPP, Stacie B. Dusetzina, PhD. Pharmaceutical Industry Payments and Oncologists’ Selection of Targeted Cancer Therapies in Medicare Beneficiaries. JAMA Intern Med. Published online April 9, 2018. doi:10.1001/jamainternmed.2018.0776